As DBM reflects on a strong 2017 and hello to a promising 2018, DBM said hello to several new faces in both its labs and offices. In the past year, DBM has added new staff and new capabilities.
In early 2017, DiscoveryBioMed hired Matthew Redmann, PhD to the post of Head of Business Development and Senior Scientist. As a recently graduated Ph.D. from the University of Alabama at Birmingham (UAB), Matthew brings with him a quality publication record and substantive interests in the business of science and how to translate discoveries at the bench to useful applications in the world. Matt is originally from Appleton, WI.
Shortly after, Lawrence Greer, J.D., LLM was appointed as Chief Financial Officer to oversee and manage the increasing complexity of DBM’s financial dealings. Lawrence earned his J.D from the University of Alabama School of Law and brings with him significant legal and business experience in the biotechnology and finance realms. Lawrence is originally from Birmingham, AL.
Alongside these additions, DBM promoted a long-term and valued intern, Albert “Os” Nakayama, to Staff Scientist. He continues to add value to scientific team in bioassay performance, scientific support, and data analysis and presentation. He is also a PowerPoint artist that has assisted on important slide deck presentations to potential partners and investors. Os is originally from Birmingham, AL.
Additional appointments include Dr. Doug Hay being added to DiscoveryBioMed’s Board of Directors. Doug brings decades of valuable biotech and pharmaceutical management experience and will be a boon to DBM as it seeks to expand its reach and navigate ever-volatile biotechnology markets. DBM has been and remains a valued consultant to DBM in Drug Discovery and Development. Doug is originally from Scotland and resides in Philadelphia.
DBM has a team with great chemistry in terms of leadership, business development and science and that will serve the company well in 2018.